XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Oct 31, 2024 | (FY)Oct 31, 2023 | (FY)Oct 31, 2022 | (FY)Oct 31, 2021 | |
---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||
Cash flow from continuing operating activities | ||||
Net income from continuing operations | 712.08%95.11M | 91.44%-15.54M | -201.80%-181.55M | --178.35M |
Change in working capital | 291.12%351.72K | 120.24%89.93K | -165.16%-444.24K | --681.81K |
-Change in receivables | 1,247.65%332.42K | 79.96%-28.97K | -185.25%-144.55K | --169.56K |
-Change in prepaid assets | -873.16%-40.47K | -47.31%5.23K | 341.41%9.93K | ---4.12K |
-Change in other current liabilities | --0 | --0 | --0 | --0 |
Cash from discontinued operating activities | ||||
Operating cash flow | 32.91%33.23M | -68.40%25M | 334.94%79.13M | ---33.68M |
Investing cash flow | ||||
Cash flow from continuing investing activities | ||||
Cash from discontinued investing activities | ||||
Financing cash flow | ||||
Cash flow from continuing financing activities | ||||
Net issuance payments of debt | -75.44%3.63M | 135.32%14.76M | -154.69%-41.8M | --76.43M |
Cash dividends paid | 0.90%-40.63M | 0.00%-41M | 0.00%-41M | ---41M |
Net other financing activities | 99.66%-11.71K | -199.66%-3.4M | --3.42M | --0 |
Cash from discontinued financing activities | ||||
Financing cash flow | -24.87%-37.01M | 62.66%-29.64M | -324.00%-79.38M | --35.44M |
Net cash flow | ||||
Beginning cash position | --0 | -3.86%4.69M | 58.38%4.88M | --3.08M |
Current changes in cash | 18.44%-3.78M | -1,791.40%-4.64M | -113.97%-245.08K | --1.75M |
Effect of exchange rate changes | 100.00%-1 | -193.60%-53.36K | 30.81%57K | --43.58K |
End cash position | ---3.78M | --0 | -3.86%4.69M | --4.88M |
Free cash flow | 32.91%33.23M | -68.40%25M | 334.94%79.13M | ---33.68M |
Currency Unit | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |